News

The Phase I/IIa trial, which is anticipated to start in the first half of 2016, will be funded and carried out by the NCI on about 55 patients.

The extension will run until November 2019 with an option to add another year. Summit will retain the exclusive rights to any intellectual property resulting from the alliance.

Roche’s option stems from a pre-existing deal with Novartis. Ophthotech’s agreement with Novartis, which was signed in May last year, remains in effect. Ophthotech retains exclusive rights to

Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is used in combination with

Turing head of research and development Eliseo Salinas said: "I’m happy to report that TUR-004 was well tolerated and assessments continue as planned. "This is certainly a small

The DMC recommendation is based upon a predefined interim analysis indicating a statistically significant benefit in efficacy for progression-free survival (PFS) and overall survival (OS) in patients receiving

The FDA previously granted Opdivo Breakthrough Therapy Designation for this indication, underscoring the critical need for new treatment options for patients with advanced RCC who have received prior

The company received notification from French pharmaceutical regulatory agency l’Agence National de Sécurité du Médicament et des produits de santé (ANSM) to suspend manufacturing within the site. Catalent

Sparsentan, also known as RE-021, is an investigational therapeutic agent which acts as a potent angiotensin receptor blocker, and a selective endothelin receptor antagonist, with in vitro selectivity